TUCSON, Ariz. , March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023 . "In 2023, we made significant progress with the development of our next-generation rapid Antibiotic Susceptibility Testing system, Accelerate Wave™. We continue to advance this important development program and believe that we remain on plan to... Read More

TUCSON, Ariz. , March 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024 , at 4:30 p.m. Eastern Time to review 2023 fourth quarter and full year results. To listen to the audio webcast online, visit ir.axdx.com . A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and... Read More

TUCSON, Ariz. , Jan. 19, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and for certain investors in lieu thereof, pre-funded units, each consisting of one pre-funded warrant to purchase one share of... Read More

TUCSON, Ariz. , Jan. 16, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, or for certain investors, pre-funded units in lieu thereof, with each pre-funded unit consisting of one-pre-funded warrant to... Read More

TUCSON, Ariz. , Jan. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2023 . "In 2023, we made significant progress with the... Read More

Working together to bring rapid, automated microbial identification directly from positive blood culture samples TUCSON, Ariz. , Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for... Read More

TUCSON, Ariz. , Nov. 9, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2023 . "During the quarter we made significant advances with our Wave program," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc. "We are getting results well within current standard of care methods to provide same-shift patient... Read More

TUCSON, Ariz. , Oct. 30, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, November 9, 2023 , at 4:30 p.m. Eastern Time to review 2023 third quarter results. To listen to the audio webcast online, visit ir.axdx.com . A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite... Read More

TUCSON, Ariz. , Aug. 10, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023 . "Throughout the quarter, we've significantly advanced our Wave Program," stated Jack Phillips , CEO of Accelerate Diagnostics, Inc. "Our recent achievements underscore our commitment to delivering a Wave pre-clinical positive blood culture... Read More

TUCSON, Ariz. , July 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, August 10, 2023 , at 4:30 p.m. Eastern Time to review 2023 second quarter results. To listen to the audio webcast online, visit ir.axdx.com . A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite... Read More

TUCSON, Ariz. , July 10, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. , (NASDAQ: AXDX) (the "Company") a leading provider of innovative rapid diagnostic solutions, announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 5:00 p.m. Eastern Time , on July 11, 2023 . The Company's common stock will begin trading... Read More

TUCSON, Ariz. , June 13, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. , (NASDAQ: AXDX) a leading provider of innovative rapid diagnostic solutions, has closed the transactions contemplated by the previously announced restructuring support agreement. Through a series of transactions, the company has simplified its capital structure, extended-out its debt maturity 3.5 years and secured $24 million of new funding,... Read More

TUCSON, Ariz. , May 11, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023 . "Our first quarter results are in line with expectations, and I am optimistic about the remainder of 2023 and beyond," commented Jack Phillips , Chief Executive Officer of Accelerate Diagnostics, Inc. "We are encouraged by our partnership with... Read More

TUCSON, Ariz. , April 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, May 11, 2023 , at 4:30 p.m. Eastern Time to review 2023 first quarter results. To listen to the audio webcast online, visit ir.axdx.com . A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite... Read More

TUCSON, Ariz. , March 29, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022 . "In 2022, we achieved another year of revenue growth thanks to our base book of satisfied customers," commented Jack Phillips , Chief Executive Officer of Accelerate Diagnostics, Inc., "Though we fell short of our guidance target, we're... Read More

TUCSON, Ariz. , March 15, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 29, 2023 , at 4:30 p.m. Eastern Time to review 2022 fourth quarter and full year results. To listen to the audio webcast online, visit ir.axdx.com . A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and... Read More

TUCSON, Ariz. , March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023 . David Patience , who previously served as Senior Director - Head of Business Development and Strategic Finance has been named as the company's new CFO,... Read More

TUCSON, Ariz. , March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023 . Jack Phillips , Chief Executive Officer of Accelerate Diagnostics, stated, "I am excited for Hany to step into this very important... Read More

TUCSON, Ariz. , Dec. 19, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest ® BC kit. Included in the submission are additional escalation and de-escalation agents for Gram-negative organisms, additional antibiotics for Acinetobacter baumannii , and... Read More